FDA re­jects As­cendis' parathy­roid can­di­date, spec­i­fy­ing man­u­fac­tur­ing con­cerns

The FDA is­sued a com­plete re­sponse let­ter to As­cendis Phar­ma for palopeg­teri­paratide, a drug-de­vice com­bi­na­tion that is be­ing test­ed as a treat­ment for hy­poparathy­roidism, cit­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER